Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.

Journal of enzyme inhibition and medicinal chemistry - 1 Dec 2014

Ehrenberg Angelica E, Schmuck Benjamin, Anwar Muhammad Ikram, Gustafsson Sofia Svahn, Stenberg Gun, Danielson U Helena

Abstract excerpt

CONTEXT: Natural strain variation and rapid resistance development makes development of broad spectrum hepatitis C virus (HCV) drugs very challenging and evaluation of inhibitor selectivity and resistance must account for differences in the catalytic properties of enzyme variants. OBJECTIVE: To understand how to study selectivity and relationships between efficacy and genotype or resistant mutants for NS3...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Cyclopropanes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lactams

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Protease Inhibitors

Share to Quinolines

Share to Thiazoles

Source

Identifiers

PMID: 24517372
DOI: 10.3109/14756366.2013.864651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.PMID 24517372Read ↗

Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.Semantic proximity Read ↗

Resistance mutations against HCV protease inhibitors and antiviral drug design.Semantic proximity Read ↗

Hepatitis C virus resistance to protease inhibitors.Semantic proximity Read ↗

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.Semantic proximity Read ↗

The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsSemantic proximity Read ↗

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Semantic proximity Read ↗

Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.Semantic proximity Read ↗

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.Semantic proximity Read ↗

Molecular mechanism by which a potent hepatitis C virus NS3-NS4A protease inhibitor overcomes emergence of resistance.Semantic proximity Read ↗

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors.Semantic proximity Read ↗

In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.Semantic proximity Read ↗

NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.